For the Inventor, By the Inventor

Enter assignee name

Houston, TX, United States of America

Immunomet Therapeutics Inc.

USPTO Granted Patents = 17

EPO Patents = 7

Trademarks = 1

Forward Citations = 47

Loading Chart...

Loading Chart...

47 inventors (with patents filed for the assignee):

Ji Sun Lee (14 out of 43 patents)

Sung Wuk Kim (13 out of 31 patents)

Hye Jin Heo (8 out of 10 patents)

4. Chang Hee Min (8 out of 9 patents)

5. Ju Hoon Oh (8 out of 9 patents)

6. Yong Eun Kim (8 out of 10 patents)

7. Hong Bum Lee (7 out of 9 patents)

8. Duck Kim (6 out of 8 patents)

9. Hong Woo Kim (6 out of 8 patents)

10. Se Hwan Park (6 out of 7 patents)

11. Ji Ae Kook (5 out of 5 patents)

12. Byung Kyu Oh (5 out of 5 patents)

13. Sung Soo Jun (4 out of 17 patents)

14. Woong Cho (3 out of 6 patents)

15. Young Woong Kim (3 out of 9 patents)

17 patents: Sort by Forward Citations

1. 12377061 - Composition for promoting hair growth comprising a guanine derivative (2025-08-05),

2. 11826324 - Pharmaceutical compositions for preventing or treating inflammatory disease, autoimmune disease, or combination thereof, and method for using same (2023-11-28),

3. 11572341 - Biguanide compound and use thereof (2023-02-07),

4. 11465989 - Guanidine compounds and use thereof (2022-10-11),

5. 10626085 - Biguanide compound and use thereof (2020-04-21),

6. 10590081 - Guanidine compounds and use thereof (2020-03-17),

7. 10376480 - Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient (2019-08-13),

8. 10252996 - N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same (2019-04-09),

9. 10221190 - Biguanide compounds and use thereof (2019-03-05),

10. 10058558 - Pharmaceutical composition comprising N1-cyclic amine-N5-substituted biguanide derivatives as an ingredient for preventing or treating fibrosis (2018-08-28),

11. 9993446 - Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient (2018-06-12),

12. 9884821 - N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same (2018-02-06),

13. 9540325 - N1-cyclic amine-N5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same (2017-01-10),

14. 9539238 - Pharmaceutical composition comprising a biguanide derivative as an active ingredient for preventing or treating glioblastoma (2017-01-10),

15. 9464042 - Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient (2016-10-11),

Company Overview

Immunomet Therapeutics Inc. is a biotechnology company based in Houston, Texas, focused on developing innovative therapies that target metabolic pathways to treat cancer and autoimmune diseases. The company specializes in harnessing the immune system's potential through its proprietary technologies, aiming to enhance patient outcomes by addressing underlying metabolic dysfunctions. With a commitment to advancing scientific research, Immunomet is positioned at the forefront of therapeutic development in the immunometabolism field.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

17 Patents

#309 in Houston, TX

#1,148 in Texas

#18,881 in US

#35,887 in the World

Houston, TX, United States of America

Immunomet Therapeutics Inc.

Forward Citations = 47

47 inventors:

Ji Sun Lee (14 out of 43 patents)

Sung Wuk Kim (13 out of 31 patents)

Hye Jin Heo (8 out of 10 patents)

4. Chang Hee Min (8 out of 9 patents)

5. Ju Hoon Oh (8 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Immunomet Therapeutics Inc.. Retrieved from https://idiyas.com/company/immunomet-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…